Brokerage Firm Rating Update on Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : The consensus on Johnson & Johnson (JNJ) based on 18 analyst recommendation on the company stock is 2.22, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 8 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Johnson & Johnson (JNJ) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $142 and the lowest price target forecast is $93. The average forecast of all the analysts is $125 and the expected standard deviation is $14.48.


For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Jefferies maintains its rating on Johnson & Johnson (NYSE:JNJ). As per the latest information, the brokerage house raises the price target to $119 per share from a prior target of $113. The shares have been rated Hold. The rating by the firm was issued on August 4, 2016.

Johnson & Johnson (NYSE:JNJ): stock was range-bound between the intraday low of $119.435 and the intraday high of $119.95 after having opened at $119.84 on Wednesdays session. The stock finally closed in the red at $119.84, a loss of -0.12%. The stock remained in the red for the whole trading day. The total traded volume was 4,753,760 shares. The stock failed to cross $119.95 in Wednesdays trading. The stocks closing price on Thursday was $119.75.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.